Arctic Therapeutics
AT-001, an oral small molecule (an NAC-amide/NACA derivative) that crosses the blood-brain barrier to disrupt amyloid plaques, targeting Alzheimer's and hereditary cystatin C amyloid angiopathy (HCCAA).
Documentation note
An identical €75,000 / October 28, 2024 funding figure appears on both this project's page and Project Transfidelity's page on cerebrumdao.com. This looks like a content-duplication artifact on CerebrumDAO's site rather than two independent €75,000 events.
The science
Problem
Amyloid plaque accumulation in Alzheimer's disease and HCCAA; sister candidate AT-004 targets inflammatory skin conditions (acne vulgaris).
Approach
Early Phase IIa data in HCCAA reportedly showed reduced amyloid deposits and halted disease progression, per the project page.
Why CerebrumDAO supported it
Not publicly documented beyond the project page's framing.
Researchers & founders
- Dr. Hakon Hakonarson, MD, PhD (Co-Founder & Chief Medical Advisor)
- Ivar Hakonarson (Co-Founder & CEO)
- Gulli Arnason (Chief Strategy Officer)
Organizations
- Research collaborations cited with Harvard, University College London, and Mass General stroke-research centers
Sources
Last reviewed: 2026-07-22